Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margaux Bossis

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Antiviral Research|May 7, 2026
Understanding HBV immunopathogenesis to inform future immune-based therapiesMargaux Bossis, Phuong-Ha Le, Tarik Asselah, et al.
Immunology|May 9, 2026
Benchmarking Dendritic Cell Enrichment Methods Reveals Subset-Specific Recovery BiasesFanny Onodi, Enwono Eyoh, Lucile Massenet-Regad, et al.
Cancer Immunology Research|June 8, 2026
ILT2 identifies an unexploited pool of intratumoral CD8+ bystander T cells with TCR-independent cytotoxicity in renal cell carcinomaRebecca Laboureur, Clément Dumont, Dzenis Koca, et al.
Iscience|February 9, 2026
BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4<sup>+</sup> Th1 responsesPaul Rollin, Benjamin Pluskwa, Emilie Artru, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Antiviral Research|May 7, 2026
Understanding HBV immunopathogenesis to inform future immune-based therapiesMargaux Bossis, Phuong-Ha Le, Tarik Asselah, et al.
Immunology|May 9, 2026
Benchmarking Dendritic Cell Enrichment Methods Reveals Subset-Specific Recovery BiasesFanny Onodi, Enwono Eyoh, Lucile Massenet-Regad, et al.
Cancer Immunology Research|June 8, 2026
ILT2 identifies an unexploited pool of intratumoral CD8+ bystander T cells with TCR-independent cytotoxicity in renal cell carcinomaRebecca Laboureur, Clément Dumont, Dzenis Koca, et al.
Iscience|February 9, 2026
BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4<sup>+</sup> Th1 responsesPaul Rollin, Benjamin Pluskwa, Emilie Artru, et al.
Pageof 1